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Lewy body (LB) pathology has been described as progressing through the brain in a 
stereotyped sequence suggesting it may spread in a trans-synaptic manner similar to 
prion protein [1]. A recent report demonstrated α-synuclein pathology in the deep 
cerebellar nuclei of LB disease cases [4]. However, the cerebellar cortex is strongly 
connected with early predilection sites in the brainstem yet had virtually no α-
synuclein pathology, indicating anatomical connectivity is not the sole determinant of 
vulnerability and cell- or region- autonomous factors may influence its development 
[5]. A previous study in wild-type mice suggested an association between regional 
expression levels of physiological α-synuclein and vulnerability to LB pathology [6]. 
However, no study has yet compared the expression of physiological α-synuclein 
across human brain regions and evaluated its relationship to α-synuclein pathology. 
Therefore, we sought to quantify regional expression levels of physiological α-
synuclein under normal conditions to evaluate its association with the topography of 
pathology in LB disease.  
We obtained fixed human brain tissue from ten cases with neocortical LB disease to 
evaluate the typical topography of LB pathology across the cortex and cerebellum 
(Supplementary Table 1). Quantitative image analysis demonstrated a consistent 
hierarchy of LB pathology severity with temporal and cingulate regions most severely 
affected, intermediate pathology in prefrontal and parietal regions, very low 
deposition in the primary visual cortex and a complete absence of LB pathology in 
the cerebellar cortex (Figure 1a).  
We next obtained frozen tissue corresponding to the same brain regions from the 
brains of eight aged cognitively normal control cases without LB disease to evaluate 
the expression of physiological α-synuclein (Supplementary Table 2). Using western 
blot analysis (Supplementary Protocol 2) we quantified α-synuclein levels across 
regions within cases. Amongst regions that typically develop LB pathology we did not 
find higher levels in regions which typically manifested the most severe LB pathology 
(Figure 1b and 1c). However, physiological α-synuclein was consistently virtually 
absent from the primary visual cortex and cerebellar cortex, regions not prone to α-
synuclein pathology (Figure 1b, Supplementary data 2). We directly compared the 
expression of physiological α-synuclein at 16 kDa in the anterior cingulate, temporal 
cortex, primary visual cortex and cerebellum as they manifested the highest and 
lowest burdens of LB pathology (Figure 1a). We found a significant main effect on α-
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synuclein levels (K-W χ²=19.8, df=3, p<0.001) and post-hoc Wilcoxon tests revealed 
significantly lower expression of α-synuclein in the primary visual cortex and 
cerebellum compared to the anterior cingulate and temporal cortex (all p<0.05).  
These results indicate physiological α-synuclein has strikingly lower expression in 
brain regions not prone to LB pathology. The recruitment of endogenous protein into 
aggregates is crucial for pathological ‘prion-like’ propagation [1] and α-synuclein 
pathology does not propagate in knockout mice [2]. Therefore, we speculate the 
cerebellum and primary visual cortex do not develop high levels of pathology in LB 
disease because propagation is significantly slowed by relatively low levels of 
physiological α-synuclein. However, as regions with the greatest proclivity to LB 
pathology did not have highest levels of physiological α-synuclein, we suggest 
physiological expression levels are not the sole determinant of vulnerability. One 
may speculate that vulnerability to LB pathology is the product of anatomical 
connectivity and region-autonomous factors, with a baseline level of physiological α-
synuclein expression necessary for pathology to develop. Our report of low 
expression levels of physiological α-synuclein in brain regions which do not typically 
develop LB is particularly important as down-regulation of physiological α-synuclein 
expression has recently been shown to exert neuroprotective qualities against LB 
diseases [3].  
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Figure 1: A consistent hierarchy of LB pathology was observed amongst cases with 
neocortical LB disease (a). Representative western blot membrane demonstrating 
low expression of physiological α-synuclein in the primary visual cortex (V1) and 
cerebellum in an aged control case (b).In controls, physiological α-synuclein was 
expressed across regions which typically develop LB but was remarkably lower in 
the primary visual cortex (V1) and cerebellum (CB; c). Western blot sample order: 
prefrontal cortex (PFC), anterior cingulate (AC), temporal cortex (TC), mid-cingulate 
(MC), posterior cingulate (PC), lateral parietal (LP), primary visual cortex (V1) and 
cerebellum (CB). 
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